Literature DB >> 27917085

Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma.

Jean-Francois H Geschwind1, Julius Chapiro2.   

Abstract

Entities:  

Year:  2016        PMID： 27917085      PMCID： PMC5114496     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.

Authors:  David P Cosgrove; Diane K Reyes; Timothy M Pawlik; Allen L Feng; Ihab R Kamel; Jean-François H Geschwind
Journal:  Radiology       Date:  2015-06-11       Impact factor: 11.105

2.  Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.

Authors:  Jean-Francois H Geschwind; Pierre M Gholam; Alec Goldenberg; Parvez Mantry; Robert C G Martin; Bilal Piperdi; Ellen Zigmont; Joanne Imperial; Svetlana Babajanyan; Pamela K Foreman; Allen Cohn
Journal:  Liver Cancer       Date:  2015-12-15       Impact factor: 11.740

Review 3.  Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.

Authors:  Ann Lii Cheng; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-François Geschwind; Khean L Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Joong-Won Park
Journal:  Liver Int       Date:  2013-11-20       Impact factor: 5.828

4.  The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.

Authors:  Yee Chao; Young-Hwa Chung; Guohong Han; Jung-Hwan Yoon; Jijin Yang; Jianhua Wang; Guo-Liang Shao; Byung Ik Kim; Teng-Yu Lee
Journal:  Int J Cancer       Date:  2014-09-16       Impact factor: 7.396

5.  TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

Authors:  Jean-François Geschwind; Masatoshi Kudo; Jorge A Marrero; Alan P Venook; Xiao-Ping Chen; Jean-Pierre Bronowicki; Lucy Dagher; Junji Furuse; Laura Ladrón de Guevara; Christos Papandreou; Arun J Sanyal; Tadatoshi Takayama; Sheng-Long Ye; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
Journal:  Radiology       Date:  2016-01-08       Impact factor: 11.105

Review 6.  Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

Authors:  Joong-Won Park; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-Francois H Geschwind; Khean Lee Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Ann-Lii Cheng
Journal:  Liver Int       Date:  2013-01-18       Impact factor: 5.828

Review 7.  Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?

Authors:  Julius Chapiro; Rafael Duran; Jean-François Geschwind
Journal:  Radiol Med       Date:  2014-06-04       Impact factor: 3.469
  7 in total
  1 in total

1.  Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.

Authors:  Ya Li; Qiuju Han; Huajun Zhao; Quanjuan Guo; Jian Zhang
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.